hydroxyurea + naproxen + sorafenib

Hydroxyurea + naproxen + sorafenib is an unapproved, investigational combination of three small-molecule drugs: hydroxyurea (a ribonucleotide reductase inhibitor that blocks DNA synthesis), naproxen (a nonsteroidal anti-inflammatory drug that inhibits cyclooxygenase enzymes), and sorafenib (a multikinase inhibitor targeting RAF, VEGFR, and PDGFR kinases). This specific triplet lacks established clinical use or unique branding, though naproxen + sorafenib shows preclinical synergy in hepatocellular carcinoma (HCC) via enhanced apoptosis through CAPN2 downregulation and PI3K/AKT inhibition. Hydroxyurea adds antineoplastic effects but introduces risks of myelosuppression when combined with sorafenib-like kinase inhibitors; no data confirms synergy or safety for the full combination, positioning it as experimental for cancers like HCC.